These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 32168325)
1. BRAF V600E mutational load as a prognosis biomarker in malignant melanoma. Sevilla A; Morales MC; Ezkurra PA; Rasero J; Velasco V; Cancho-Galan G; Sánchez-Diez A; Mujika K; Penas C; Smith I; Asumendi A; Cortés JM; Boyano MD; Alonso S PLoS One; 2020; 15(3):e0230136. PubMed ID: 32168325 [TBL] [Abstract][Full Text] [Related]
2. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma. Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765 [TBL] [Abstract][Full Text] [Related]
3. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424 [TBL] [Abstract][Full Text] [Related]
4. Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases. Nielsen LB; Dabrosin N; Sloth K; Bønnelykke-Behrndtz ML; Steiniche T; Lade-Keller J Histopathology; 2018 Apr; 72(5):814-825. PubMed ID: 29119584 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature. Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650 [TBL] [Abstract][Full Text] [Related]
6. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan. Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807 [TBL] [Abstract][Full Text] [Related]
7. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry. Yaman B; Kandiloğlu G; Akalin T Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683 [TBL] [Abstract][Full Text] [Related]
10. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143 [TBL] [Abstract][Full Text] [Related]
11. Lymph node metastases of melanoma: challenges for BRAF mutation detection. Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393 [TBL] [Abstract][Full Text] [Related]
12. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis. Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298 [TBL] [Abstract][Full Text] [Related]
13. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods. O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937 [TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of the BRAF Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702 [TBL] [Abstract][Full Text] [Related]
16. Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies. Lamy PJ; Castan F; Lozano N; Montélion C; Audran P; Bibeau F; Roques S; Montels F; Laberenne AC J Mol Diagn; 2015 Jul; 17(4):366-73. PubMed ID: 25952101 [TBL] [Abstract][Full Text] [Related]
17. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction. Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117 [TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Bucheit AD; Syklawer E; Jakob JA; Bassett RL; Curry JL; Gershenwald JE; Kim KB; Hwu P; Lazar AJ; Davies MA Cancer; 2013 Nov; 119(21):3821-9. PubMed ID: 23922205 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]